Defending and Explaining Rapamycin (Matt Kaeberlein on Twitter)

4 Likes

Great thread, thanks for sharing

1 Like

The 30 or so bona fide anti-ageing companies that exist are more interested in developing their own proprietary therapies than readily accessible drugs such as Rapamycin, metformin, dasatinib and quercetin. Until additional funding can be found, this means that safe, affordable drugs with the potential to slow ageing and extend the healthspan are not being properly explored

James - I agree that this is an issue. Its great to have the commercial focus on anti-aging drugs - but its going to take 20+ years for those results to filter down to most people. I think the NIH / National Institute on Aging needs to develop a ITP RCT program focused on identifying generic drug candidates for anti-aging and fund some major phase 2 clinical trials for age mitigation.